LIVINGSTONE
HEALTH

PRESS RELEASE

1H2027 Financial Results

Livingstone Health's Net Profit surges 293.2% to S$924,000 for 1H2027; reports higher revenue and margin on improved operational efficiencies

Livingstone Health reports significant improvement in its financial performance for 1H2027 compared to 1H2026:

- ***Revenue up 9.6% to S$16.2 million, contributed from the Group's key operating segments (Specialist Healthcare and Primary Healthcare).***
- ***Net Profit almost quadrupled to S$924,000, surpassing the Group's accumulated Net Profit of S$780,000 for both FY2025 and FY2026, following operational restructuring and cost rationalisation initiatives.***
- ***Net margin was 5.6%, up from 0.2% on improved operational efficiencies.***

Singapore, 10 November 2026 – Livingstone Health Holdings Limited ("**Livingstone Health**" or the "**Company**", together with its subsidiaries, the "**Group**") today reported its unaudited financial results for the six-month ended 30 September 2026 ("**1H2027**"), reflecting a significant improvement compared to that of 1H2026.

FINANCIAL PERFORMANCE HIGHLIGHTS FOR 1H2027

Figures in S$'000	1H2027	1H2026	Change
Revenue	16,241	14,820	9.6%
Net profit attributable to owners of the Company ("**Net Profit**")	924	235	293.2%

The Group reported higher revenues of S$16.2 million in 1H2027, up 9.6% from S$14.8 million in 1H2026, driven primarily by higher contributions from the Group's key operating segments (Specialist Healthcare and Primary Healthcare).

Cost for consumables and medical supplies and other operating expenses (marketing-related in particular) increased in 1H2027 on the back of higher revenue while employee benefit expenses increased due to the expansion of clinical teams and higher performance-based compensation.

The Net Profit almost quadrupled in 1H2027, rising 293.2% to approximately S$924,000, compared to S$235,000 in 1H2026. Net Profit for 1H2027 alone had also exceeded the Group's combined Net Profits of S$780,000 from both FY2025 and FY2026, reflecting the financial effects as a result of operational restructuring plans, cost rationalisation exercise and strategic investments initiated by the Group over the last two financial years. Net margin improved to 5.6% in 1H2027, from 0.2% in 1H2026.

The improved financial performance was also backed by a healthy net operating cash flows of S$1.8 million generated by the Group during 1H2027. The Group, while monitoring its supply chain related

costs closely, had made several strategic decisions during FY2025 and FY2026. Specifically, as previously announced, it closed the underperforming Ardennes health screening centre to rationalise operations; invested in an endocrinology specialist clinic and a colorectal and general surgery clinic; and acquired another primary care clinic. These initiatives have since improved operational efficiencies, enhanced healthcare ecosystem, expanded patient outreach and optimised cross-referral networks.

The equity attributable to the owners of the Company increased from S$6.9 million as at 31 March 2026 to S$8.0 million as at 30 September 2026, which include cash and cash equivalents of S$2.6 million. Loans and bank borrowings were S$3.1 million, such that the Group had a net debt position of S$0.5 million as at 30 September 2026.

Commentary

Commenting on the Group's results, Dr. Wilson Tay, Executive Director and CEO of Livingstone Health, said, "Building on our higher earnings base and improved operational efficiencies, we will continue to grow our team of doctors and healthcare professionals while evaluating other accretive investments which could further strengthen cross-referrals healthcare ecosystem across our medical disciplines.

In addition to the recent closure of the health screening centre, the Group also invested in an endocrinology specialist clinic and a colorectal and general surgery clinic, as announced in April 2025 and December 2025 respectively, and acquired another primary care clinic in March 2026, expanding the network of Phoenix Medical Group."

The Group has also invested in digitalisation efforts by adopting data analytics across its operations to better understand its patient needs, and enhance cross-referrals among its medical disciplines, for more proactive and personalised healthcare experience for improving patient outcomes.

As at 30 September 2026, the Group secured an aggregate banking facilities of S$7.0 million, of which S$3.75 million had been utilized to primarily fund strategic acquisitions, working capital and capital expenditure as the Group continues to execute its growth strategies.

Meanwhile, the highly competitive medical talent and workforce market, increasing supply chain and operating costs have further led to cost-push inflation in the industry that the Group remains cautious amidst the challenging operating environment.

– End –

About Livingstone Health

Livingstone Health Holdings Limited ("**Livingstone Health**" and together with its subsidiaries, the "**Group**") is a Singapore-based multidisciplinary healthcare group whose core competencies include Specialist Healthcare and Primary Healthcare.

The name "Livingstone" is inspired by the succulent plant Lithops, also known as "living stones". They symbolise the Group's resilience, growth and determination to be recognised as a trusted integrated healthcare provider for patients, as well as a centre of excellence for growth opportunities for medical professionals.

The Group currently operates 21 clinics with 25 medical specialists and practitioners, including a medical aesthetics clinic and a podiatry clinic situated in convenient and accessible locations throughout Singapore. It also provides healthcare consultancy services within the region.

For more information, please visit www.livingstonehealth.com.sg.

Media & Investor Contact Information

Wong Qingyuan
Chief Financial Officer
217 Henderson Road, #01-09 Henderson Industrial Park, Singapore 159555
+65 6932 7721 | Email: ir@livingstonehealth.com.sg

This press release has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). This press release has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Lee Khai Yinn (Telephone: (65) 6232 3210) at 1 Robinson Road, #21-01, AIA Tower, Singapore 048542.